Navigation Links
Skin transplant offers new hope for vitiligo patients
Date:5/30/2012

DETROIT Henry Ford Hospital dermatologists say skin transplant surgery is safe and effective for restoring skin pigmentation caused by the skin disease vitligo.

In a first study of its kind in the United States, researchers followed 23 patients for up to six months after surgery and found that the treated area regained on average 43 percent of its natural skin color. In eight patients with localized vitiligo, the treated area regained on average 68 percent of its natural skin color.

The surgery involves using skin cells taken from healthy, normally pigmented areas of the body and transferring them to the damaged area of skin. It is performed under local anesthesia.

The study is published in the May edition of the Journal of the American Academy of Dermatology. It is available online at http://www.eblue.org/article/S0190-9622(11)00527-5/abstract.

"The results achieved in our study were of obvious significance to our patients," says Iltefat Hamzavi, M.D., a senior staff physician in Henry Ford's Department of Dermatology and the study's senior author and principal investigator. "We believe this new treatment option offers hope to patients of color and those with vitiligo on one side of the body or in one area of the body."

Vitiligo is a skin disease that causes the skin to lose color and develop white patches that vary in size and location. It affects about 1 in every 200 people in the United States, and is more noticeable in people with darker skin. Standard treatments include light therapy and topical medications.

Vitiligo develops when cells called melanocytes are killed by the body's immune system, causing the area of skin to turn white because the cells no longer make pigment. While there is no cure, vitiligo can be treated and managed with light therapy, creams and topical medications.

The surgery is known as melanocyte-keratinocyte transplantation, or MKTP, and is performed in Europe, Asia and the Middle East. It was performed at Henry Ford using the same technique developed by MKTP pioneer Sanjeev Mulekar, M.D., of the National Vitiligo Center in Saudi Arabia. Henry Ford is the first to perform MKTP in North America.

In Henry Ford's study, 28 patients underwent surgery and ranged in age from 18 to 60. A total of 36 MKTP procedures were performed and researchers analyzed the outcomes of 29 of them. The procedure lasted 30 minutes to two hours and patients returned home the same day.

Of the 28 surgery patients, 23 were followed for up to six months after surgery. Eighteen patients received one treatment, four patients received two and one patient received three. The ethnicity of patients was Caucasian, South Asian, African American and Hispanic.

During MKTP, melanocyte cells, which produce pigment in the skin, hair and eyes, are harvested from an area of healthy skin and separated to make a skin cell mixture. This mixture then is applied to the treatment area and covered with a specially developed adhesive biologic dressing.

Treated areas included the hands, arms, legs, feet, face and stomach. The average size of the treated area during each procedure was 46 cm2, or roughly the size of a credit card.


'/>"/>

Contact: David Olejarz
David.Olejarz@hfhs.org
313-874-4094
Henry Ford Health System
Source:Eurekalert  

Related medicine news :

1. New drug for kidney transplant recipients effective in humans
2. WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday
3. Spanish Only, Please: Special Latino Clinic Launched For Potential Abdominal Transplant Patients
4. WellPoint/Blue Cross Liver Transplant Denial Trial Begins Today, Illustrates Need for Toughening of White House Reform Plan
5. Newer cornea transplant surgery shows short- and long-term promise
6. Cristophe Salon in Beverly Hills Teams Up with Mad Men Actor to Help Raise Money for His 17-Year-Old Cousins Heart Transplant
7. Two Babies Born a Year Apart After Ovary Transplant
8. Wounded Soldier Who Received Historic Cell Transplant Gets Standing Ovation at Diabetes Research Institute Benefit
9. Internal Anthem Blue Cross/WellPoint Document: Only Patients Who Push Back Get Covered Out of State Liver Transplants
10. Drug dramatically reduces nausea and vomiting in bone marrow transplant patients
11. Kidney Patients From Across South Carolina Visit State Capitol to Encourage Policies that Improve Patient Access to Life-Saving Dialysis and Transplant Care
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Skin transplant offers new hope for vitiligo patients
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that services the ... Eastern Michigan last Friday in order to aid in the Flint water crisis. In ... a facility located in Clio, only 15 miles away from Flint. , “We have ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand ... within Healthcare, recently partnered with Heart City Health Center to improve ... 23 years, Heart City Health Center has provided the Elkhart community with access ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... 10 ... Brand. There were three leading bottled water brand owners that topped the list as ... enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged to ... shows that the Goal Attainment Scale (GAS) captures 20% more change in outcomes ... more about the Goal Attainment Scale, Education Resources Inc. is offering a course ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... and PITTSBURGH, Feb. 10, 2016 Mylan N.V. (NASDAQ, ... quarter and year ended December 31, 2015. ... Full year adjusted total revenues of $9.45 billion, up ... year; GAAP total revenues of $9.43 billion. Excluding the ... markets specialty and branded generics business (the "EPD Business"), ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology: